You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Last Updated: February 26, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for TAK-593

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug TAK-593?

TAK-593 is an investigational drug.

There have been 321 clinical trials for TAK-593. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2016.

The most common disease conditions in clinical trials are Diabetes Mellitus, Hypertension, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and National Cancer Institute (NCI).

There are three US patents protecting this investigational drug and twenty-one international patents.

Recent Clinical Trials for TAK-593
A Pharmacokinetic and Safety Study of TAK-925 in Participants With Idiopathic HypersomniaMillennium Pharmaceuticals, Inc.Phase 1
A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C] TAK-831 in Male Healthy ParticipantsTakedaPhase 1
A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori InfectionTakedaPhase 3

See all TAK-593 clinical trials

Clinical Trial Summary for TAK-593

Top disease conditions for TAK-593
Top clinical trial sponsors for TAK-593

See all TAK-593 clinical trials

US Patents for TAK-593

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
TAK-593   Start Trial Imidazopyridazine derivative having kinase inhibitory activity and pharmaceutical agent thereof Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
TAK-593   Start Trial Fused heterocyclic derivative and use thereof Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
TAK-593   Start Trial Imidazo-pyridazinyl compounds and uses thereof Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.